Mechanisms of drug resistance in chemotherapy for urogenital carcinoma

International Journal of Urology

Volumn 6, Issue 9, 1999, Pages 427-439

  Naito, Seiji ^a   Yokomizo, Akira ^a,b   Koga, Hirofumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Anticancer drug; Chemotherapy; Multidrug resistance; Review; Urogenital cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXVERAPAMIL; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IFOSFAMIDE; METALLOTHIONEIN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; QUINIDINE; TENIPOSIDE; THIOREDOXIN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; MALE; P-GLYCOPROTEINS; SULFHYDRYL COMPOUNDS; UROGENITAL NEOPLASMS;

EID: 0032885328     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.00088.x     Document Type: Review

References (100)

1. 1 Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N. Engl. J. Med. 1997; 337: 242-53.
2. 2 Rao PH, Houldsworth J, Palanisamy N et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998; 58: 4260-3.
3. 3 van Brussel JP, Mickisch GH. Circumvention of multidrug resistance ingenitourinary tumors. Int J. Urol. 1998; 5: 1-15.
4. 4 Roninson IB, Chin JE, Choi KG et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl Acad. Sci. USA 1986; 83: 4538-42.
5. 5 Chen CJ, Chin JF., Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
6. 6 Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
7. 7 Borst P, Kool M, Evers R. Do cMOAT (MRP2), other MRP homologues, und LRP play a role in MDR? Semin.. Cancer Biol. 1997; 8: 205-13.
8. 8 Taniguchi K, Wada M, Kohno K et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed incisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996; 56: 4124-9.
9. 9 Lomri N, Fitz JG, Scharschmidt BF. Hepatocellular transport: Role of ATP-binding cassette proteins. Semin. Liver Dis. 1996; 16: 201-10.
10. 10 Aszalos A, Ross DD. Biochemical and clinical aspects of efflux pump-related resistance to anti-cancer drugs. Anticancer Res. 1998; 18: 2937-44.
11. 11 Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 1997; 8: 161-70.
12. 12 Ueda K, Okamura N, Hirai M et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem 1992; 267: 24 248-52.
13. 13 Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood· brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
14. 14 Hasegawa S, Abe T, Naito S et al. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer 1995; 71: 907-13.
15. 15 Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994; 54: 152-8.
16. 16 Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994; 54: 4833-6.
17. 17 Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem 1994; 269: 27 807-10.
18. 18 Muller M, Meijer C, Zaman GJ et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent-glutathione S-conjugate transport. Proc. Natl Acad. Sci. USA 1994; 91: 13033-7.
19. 19 Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994; 54: 357-61.
20. 20 Cole SP, Sparks KE, Fraser K et al. Pharmacological characterization of multidrug resistant MRP-transfeeted human tumor cells. Cancer Res. 1994; 54: 5902-10.
21. 21 Deeley RG, Cole SP. Function, evolution and structure of multidrug resistance protein (MRP). Semin. Cancer Biol. 1997; 8: 193-204.
22. 22 Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57: 3537-47.
23. 23 Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression ofhuman MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. 1999; 59: 175-82.
24. 24 Miyake K, Mickley L, Litman T et al. Molecular cloning of cDNAs which are highly ovcrexprcssed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res. 1999; 59: 8-13.
25. 25 Paulusma CC, Kool M, Bosma PJ et al. A mutation in the human cMOAT gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-42.
26. 26 Wada M, Toh S, Taniguchi K et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 1998; 7: 203-7.
27. 27 Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M, Kuwano M. A canalicular multispecific organic anion transporter (cMOAT) antiscnse cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997; 57: 5475-9.
28. 28 Uchiumi T, Hinoshita E, Haga S et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem. Biophys. Res. Commun. 1998; 252: 103-10.
29. 29 Scheffer GL, Wijngaard PLJ, Flens MJ et al. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1995; 1: 578-82.
30. 30 List AF, Spier CS, Grogan TM et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-9.
31. 31 Meister A, Anderson M. Glutathione. Annu. Rev. Biochem. 1983; 52: 711-60.
32. 32 Ziegler DM. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu. Rev. Biochem. 1985; 54: 305-29.
33. 33 Yokomizo A, Kohno K, Wada M et al. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis. J. Biol. Chem 1995; 270: 19451-7.
34. 34 Tew KD. Glutathione-associated enzymes in anti cancer drug resistance. Cancer Res. 1994; 54: 4313-20.
35. 35 Meister A. Glutathione, ascorbate, and cellular protection. Cancer Rex. 1994; 54: 1969s-75s.
36. 36 Ozols RF, Hamilton TC, Masuda H, Young RC. Novel drugs that affect glutathione metabolism. In: Woolley PV III, Tew KD (eds). Mechanisms of Drug Resistance in Neoplastic Cells. Academic Press, New York, 1988; 289-306.
37. 37 Miyazaki M, Kohno K, Saburi Y et al. Biochem. Biophys. Res. Commun. 1990; 166: 1358-64.
38. 38 Nakagawa K, Saijo N, Tsuchida S et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfeetant cell lines. J. Biol. Chem. 1990; 265: 4296-301.
39. 39 Richman PG, Meister A. Regulation of gamma-glutamyl-cysteinesynthetase by non-allosteric feedback inhibition by glutathione. J. Biol. Chem 1975; 250: 1422-6.
40. 40 Mulcahy RT, Bailey HH, Gipp JJ. Transfeetion of complementary DNAs for the heavy and light sub-units of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan. Cancer Res. 1995; 55: 4771-5.
41. 41 Kurokawa H, Ishida T, Nishio K et al. Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem. Biophys. Res. Commun 1995; 216: 258-64.
42. 42 Yokomizo A, Ono M, Nanri H et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995; 55: 4293-6.
43. 43 Kawahara N, Tanaka T, Yokomizo A et al. Enhanced coexpression of thioredoxin and high mobility group protein I genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res. 1996; 56: 5330-3.
44. 44 Sasada T, Iwata S, Sato N et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): Protective effect of humanthioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest 1996; 97: 2268 76.
45. 45 Wang J, Kobayashi M, Sakurada K, Imamura M, Moriuchi T, Hosokawa M. Possible roles of an adult T-cell leukemia (ATL) -derived factor/thioredoxin in the drug resistance of ATL to adriamycin. Blood 1997; 89: 2480-7.
46. 46 Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Overexpression of thioredoxin docs not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines. Cancer Chemotherpharmacol. 1997; 40: 31-7.
47. 47 Lazo JS, Kuo SM, Woo ES, Pitt BR. The protein thiol metallothionein as an antioxidant and protectant against antincoplastic drugs. Chem Biolinteract 1998; 24: 255-62.
48. 48 Kasahara K, Fujiwara Y, Nishio K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 1991; 51: 3237-42.
49. 49 Kotoh S, Naito S, Sakamoto N, Goto K, Kumazawa J. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J. Urol. 1994; 152: 1267-70.
50. 50 Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379: 225-32.
51. 51 Wang JC. DNA topoisomerases. Annu. Rev. Biochem. 1996; 65: 635-69.
52. 52 Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49: 11-19.
53. 53 Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucl. Acids Res. 1992; 20: 5587-92.
54. 54 Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol. 1993; 4: 533-43.
55. 55 Matsuo K, Kohno K, Takano H, Sato S, Kiue A, Kuwano M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res. 1990; 50: 5819-24.
56. 56 Kubo T, Kohno K, Ohga T et al. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res. 1995; 55: 3860-4.
57. 57 Matsuo K, Kohno K, Sato S et al. Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Res. 1993; 53: 1085-90.
58. 58 Furukawa M, Uchiumi T, Nomoto M et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase II alpha gene by heat shock. J. Biol. Chem 1998; 273: 10 550-5.
59. 59 Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur. Urol. 1993; 24: 156-60.
60. 60 Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: Correlation with grade-and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J. Natl Cancer Inst. 1989; 81: 844-9.
61. 61 Kakehi Y, Kanamaru H, Yoshida O et al. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J. Urol. 1988; 139: 862-5.
62. 62 Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J. Urol. 1996; 156: 506 11.
63. 63 Volm M, Mattern J, Efferth T, Pommerenke EW. Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anti-cancer Res. 1992; 12: 1063-7.
64. 64 Naito S, Koike K, Ono M et al. Development of novel reversal agents, Imidazothiazole derivatives, targeting MDR1-and MRP-mediated multidrug resistance. Oncol. Res. 1998; 10: 123-32.
65. 65 Motzer RJ, Lyn P, Fischer P et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J. Clin. Oncol. 1995; 13: 1958-65.
66. 66 Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J, Skorecki KL. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Ant. J. Clin. Oncol. 1995; 18: 251-6.
67. 67 Agarwala SS, Bahnson RR, Wilson JW, Szumowski J, Ernstoff MS. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma: A phase I study. Am. J. Clin. Oncol. 1995; 18: 211-15.
68. 68 Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest. New Drugs 1994; 12: 137-41.
69. 69 Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma: A Hoosier Oncology Group Study. Am. J. Clin. Oncol. 1994; 17: 10-13.
70. 70 Kimiya K, Naito S, Soejima T et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J. Urol. 1992; 148: 441-5.
71. 71 Naito S, Hasegawa S, Yokomizo A et al. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. Jpn. J. Cancer Res. 1995; 86: 1112-18.
72. 72 Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J. Enhanced expression of gamma-glutamyl cysteine synthetase and glutathioneS-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J. Urol. 1997; 157: 1054-8.
73. 73 Kotoh S, Naito S, Yokomizo A et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothein in human cisplatin-resistant bladder cancer cells. Cancer Res. 1994; 54; 3248-52.
74. 74 Rowinsky EK, Kaufmann SH, Baker SD et al. Sequences of topotecan and cisplatin: Phase I, pharmacologie, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 1996; 14: 3074-84.
75. 15 Hisano T, Ono M, Nakayama M, Naito S, Kuwano M, Wada M. Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: Identification by mRNA differential display. FEBS Lett 1996; 397; 101-7.
76. 76 Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 1994; 54: 5255-7.
77. 77 van der Meijden AP. Bladder cancer. BMJ 1998; 317: 1366-9.
78. 78 Herr HW, Loudone VP, Whitmore WF Jr An overview of intravesical therapy for superficial tumours. J. Urol. 1987; 138: 1363-8.
79. 79 Naito S, Kotoh S, Omoto T et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: A randomized controlled trial of doxorubicin-plus verapamil versus doxorubicin alone: The Kyushu University Urological Oncology Group. Cancer Chemother. Pharmacol. 1998; 42: 367-72.
80. 80 Lukkarinen O, Paul C, Hellstrom P et al. Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand. J. Urol Nephrol. 1991; 25: 25-8.
81. 81 Nakagawa M, Emoto A, Nasu N et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J. Urol. 1997; 15: 1260-5.
82. 82 Katagiri A, Tomita Y, Nishiyama T, Kimura M, Sato S. Immunohistochemical detection of P-glycoprotein and GSTPI-I in testis cancer. Br. J. Cancer 1993; 68: 125-9.
83. 83 Masters JR, Thomas R, Hall AG, Hogarth L, Matheson EC, Cattan AR, Lohrer H. Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways. Eur: J. Cancer 1996; 32: 1248-53.
84. 84 Eid H, Van der Looij M, Institoris E et al. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res. 1997; 17: 2663-9.
85. 85 Houldsworth J, Xiao H, Murty VV et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998; 16: 2345-9.
86. 86 Rao PH, Houldsworth J, Palanisamy N et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998; 58: 4260-3.
87. 87 International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 1997; 15: 594-603.
88. 88 Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin. Oncol. 1998; 25 (Suppl. 4): 24-32.
89. 89 Haas N, Hudes GR. Genito-urinary malignancy. Cancer Chemother Biol. Response Modif. 1997; 17: 504-35.
90. 90 Petrovich Z, Baert L, Bagshaw MA et al. Adenocarcinoma of the prostate: Innovations in management. Am. J. Clin. Oncol. 1997; 20: 111-19.
91. 91 Koivisto P, Kulmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol. 1998; 152: 1-9.
92. 92 Arai Y, Yoshida O. A heterogeneous pattern of progression in endocrine-treated patients with prostate cancer. Eur: Urol. 1996; 29: 331-6.
93. 93 Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993; 71 (Suppl. 3): 1098-109.
94. 94 Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostalic glandular cells induced by androgen ablation. Proc. Natl Acad. Sci. USA 1993; 90: 8910-14.
95. 95 Siegsmund MJ, Kreukler C, Steidler A, Nebe T, Kohrmann KU, Alken P. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol. Res. 1997; 25: 35-41.
96. 96 Izbicka E, Dalton WS, Troyer D, Von Hoff DD. Expression of two multidrug resistance genes in human prostatic carcinomas. J. Natl Cancer Inst. 1998; 90: 166-7.
97. 97 Nakagawa M, Nomura Y, Kohno K et al. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J. Urol. 1970; 1993: 150-3.
98. 98 Hudes G. Estramustine-based chemotherapy. Semin. Urol. Oncol. 1997; 15: 13-19.
99. 99 Oh WK, Kantoff PW. Management of hormone refractory prostate cancercurrent standards and future prospects. J. Urol. 1998; 160: 1220-9.
100. 100 Speicher LA, Barone LR, Chapman AF, et al. P-glycoprotein binding and modulation of the multidrug-resistanl phenotype by estramustine. J. Natl Cancer Inst. 1994; 86: 688-94.